Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 17, 2020 (6 years ago)

Ascend Laboratories (Cephalexin)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurity/Degradation Specifications

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Ascend Laboratories, llc Cephalexin for Oral Suspension, USP 250 mg per 5 mL 100 ml (when mixed) Rx Only Manufactured by: Alkem Laboratories, Ltd, Mumbai -400 013 INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-545-88

Affected NDC 67877-0545-88

Compare with the code on your package — it is the most precise check available.

Drug: Cephalexin Category: Antibiotic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Cephalexin
NDC 67877-0545
250 mg/5mL For Suspension
Oral
Ascend Laboratories, LLC Rx
Recalling firm
Ascend Laboratories LLC
NDC code
67877-545-88
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0178-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cephalexin recalls

See all
Class II · Moderate risk

Cephalexin for Oral Suspension

Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 67877-544-68 D-0469-2025
Class II · Moderate risk

Cephalexin for Oral Suspension

Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 67877-544-88 D-0468-2025
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-9207-1 D-0540-2024
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states Each contains: cephalexin monohydrate, USP equivalent to 5g' on the back label instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 5g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-9206-1 D-0539-2024
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-8858-1 D-0538-2024

Other recalls by Ascend Laboratories LLC

All 2020 recalls
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7253-04 D-0739-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7253-68 D-0738-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7255-68 D-0737-2026